AbCellera reported positive Phase 2 topline results for ABCL635, an NK3R antagonist antibody intended as a long-acting, non-hormonal option for moderate-to-severe vasomotor symptoms due to menopause. In a randomized, double-blind, placebo-controlled multicenter study, a single 600 mg subcutaneous dose met primary endpoints at week 4, improving both frequency and severity versus placebo. The trial enrolled 92 postmenopausal women with a baseline mean of about 10 moderate-to-severe hot flashes per day. AbCellera said ABCL635 reduced VMS frequency by 8.8 events per day at week 4 compared with 3.5 for placebo, and also improved sleep and patient global impression of change. Clinically, the headline for investors and developers is durability-by-dosing: ABCL635’s single-dose design aims to simplify administration while delivering a magnitude of symptom reduction that AbCellera describes as a new benchmark for the class, setting up the Phase 3 question of whether the effect persists and remains safe.